Réjean Thomas

Réjean Thomas

Auto-generated profile, based on publicly available information

Réjean Thomas

Clinique médicale l'Actuel, Montréal, QC, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
JAJorge Luis Flores Anato
Jorge Luis Flores Anato
DPDimitra Panagiotoglou
Dimitra Panagiotoglou
ZGZoë R. Greenwald
Zoë R. Greenwald
CTClaire Trottier
Claire Trottier
MVMaliheh Vaziri
Maliheh Vaziri
MMMathieu Maheu-Giroux
Mathieu Maheu-Giroux
Chemsex among gay, bisexual and other men who have sex with men (gbMSM) has raised public health concerns because of its association with sexual behaviours that can increase transmission of sexually transmitted infections, including HIV. Pre-exposure prophylaxis (PrEP) is highly effective at blocking HIV acquisition, addressing important prevention needs among individuals practicing chemsex. This study aims to improve our understanding of chemsex practices and PrEP trajectories of gbMSM and transgender women consulting for PrEP. We used data from the PrEP cohort of Clinique médicale l'Actuel, a major sexual health clinic in Montréal. We describe the sociodemographic profile of clients consulting for PrEP, characterize chemsex and polysubstance use trends over time, and evaluate PrEP trajectories using Kaplan-Meier curves. Among 2923 clients who consulted for PrEP between 2013-2020 (2910 cisgender gbMSM, 6 transgender gbMSM, 7 transgender women), 24 % reported chemsex in the past year and 13 % reported polysubstance use. The most common chemsex substances were ecstasy (14 %), GHB (13 %), and cocaine (12 %). The proportion of clients reporting chemsex and polysubstance use decreased over time. In both the chemsex and no-chemsex group, 73 % of clients initiated PrEP. The median time to discontinuation was similar between the chemsex (6.5 months; 95 %CI: 5.3-7.2) and no-chemsex group (6.9 months; 95 %CI: 6.3-7.5). Chemsex is not a barrier to PrEP initiation or persistence. However, these results suggest a high prevalence of chemsex among gbMSM consulting for PrEP, highlighting the need for services addressing the intersection of sexual health and substance use for this population.

27 November 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
NPNitika Pant Pai
Nitika Pant Pai
MMegan Smallwood
Megan Smallwood
LDLaurence Desjardins
Laurence Desjardins
AGAlexandre Goyette
Alexandre Goyette
KBKrisztian G Birkas
Krisztian G Birkas
RTRéjean Thomas
Réjean Thomas
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

15 March 2002 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
GAGalit Alter
Galit Alter
AMAlefia Merchant
Alefia Merchant
CTChristos M. Tsoukas
Christos M. Tsoukas
DRDanielle Rouleau
Danielle Rouleau
RLRoger P. LeBlanc
Roger P. LeBlanc
NBNicole Flore Bernard
Nicole Flore Bernard
The interferon-γ ELISPOT assay was used to assess and compare the magnitude and breadth of human immunodeficiency virus (HIV)-specific CD8 T cell responses in treatment-naive subjects during the first year of HIV primary infection and during the chronic phase of infection. Twenty-five subjects tested within a year of exposure to HIV resulting in seroconversion and 20 subjects with chronic infection were screened for HIV peptide-specific activity by stimulating peripheral blood mononuclear cells with a panel of 5–21 HLA class I-restricted HIV peptides (mean, 11.2 ± 3.5 HIV peptides). There was a significant correlation between the magnitude and breadth of HIV-specific effector responses and time elapsed from exposure (r = 0.63 for magnitude vs. time and r = 0.64 for breadth vs. time; P < .02, paired t test). Maximal breadth of the HIV gene product reactivity was achieved within 2 months of exposure for Nef-specific responses and by 4 months of exposure for responses directed to Env, Gag, and reverse transcriptase.

20 April 2020 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
JCJosé Côté
José Côté
GRGeneviève Rouleau
Geneviève Rouleau
MRMaria Pilar Ramirez-Garcia
Maria Pilar Ramirez-Garcia
PAPatricia Auger
Patricia Auger
RTRéjean Thomas
Réjean Thomas
JLJudith LEBLANC
Judith LEBLANC
Background: Taking antiretroviral therapy (ART) is part of the daily life of people living with HIV. Different electronic health (eHealth) initiatives adjunctive to usual care have been proposed to support optimal medication adherence. A web-based intervention called HIV Treatment, Virtual Nursing Assistance, and Education or VIH-TAVIE (from its French version Virus de l’immunodéficience humaine-Traitement assistance virtuelle infirmière et enseignement) was developed to empower people living with HIV to manage their ART and symptoms optimally. Objective: We aimed to evaluate the effectiveness of VIH-TAVIE in a web-based randomized controlled trial (RCT). Methods: This RCT was entirely web-based, including recruitment, consent granting, questionnaire completion, and intervention exposure (consultation with VIH-TAVIE [experimental group] or websites [control group]). To be eligible for the study, people living with HIV had to be 18 years or older, be on ART for at least 6 months, have internet access, and have internet literacy. Participants were randomly assigned to either the experimental group (n=45) or control group (n=43). The primary outcome was ART adherence. The secondary outcomes included self-efficacy regarding medication intake, symptom-related discomfort, skills and strategies, and social support. All outcomes were measured with a self-administered web-based questionnaire at the following three time points: baseline and 3 and 6 months later. A generalized linear mixed model was built to assess the evolution of ART adherence over time in both groups. Results: The sample included 88 participants, and of these, 73 (83%) were men. The median age of the participants was 42 years. Participants had been diagnosed with HIV a median of 7 years earlier (IQR 3-17) and had been on ART for a median of 5 years (IQR 2-12). The proportion of treatment-adherent participants at baseline was high in both groups (34/41, 83% in the experimental group and 30/39, 77% in the control group). Participants also reported high treatment adherence, high self-efficacy, and high skills; perceived good social support; and experienced low discomfort from symptoms. Analyses revealed no intergroup difference regarding ART adherence (OR 1.9, 95% CI 0.6-6.4). Conclusions: This study highlights the challenges and lessons learned from conducting an entirely web-based RCT among people living with HIV. The challenges were related to the engagement of people living with HIV on the following three levels: starting the web-based study (recruitment), completing the web-based intervention (engagement), and continuing the study (retention). The results contribute to the existing body of knowledge regarding how to conduct web-based evaluation studies of eHealth interventions aimed at developing and strengthening personal skills and abilities. Trial Registration: ClinicalTrials.gov NCT01510340; https://clinicaltrials.gov/ct2/show/NCT01510340

26 February 2021 in Sociology of Health & Illness
Verified
Journal Article
Open access
PDF file
RJRicky Janssen
Ricky Janssen
NENora Engel
Nora Engel
NPNitika Pant Pai
Nitika Pant Pai
AEAliasgar Esmail
Aliasgar Esmail
KDKeertan Dheda
Keertan Dheda
AKAnja Krumeich
Anja Krumeich
Mobile health (mHealth) technologies for HIV care are developed to provide diagnostic support, health education, risk assessment and self‐monitoring. They aim to either improve or replace part of the therapeutic relationship. Part of the therapeutic relationship is affective, with the emergence of feelings and emotion, yet little research on mHealth for HIV care focuses on affect and HIV testing practices. Furthermore, most of the literature exploring affect and care relations with the introduction of mHealth is limited to the European and Australian context. This article explores affective dimensions of HIV self‐testing using a smartphone app strategy in Cape Town, South Africa and Montréal, Canada. This study is based on observation notes, 41 interviews and 1 focus group discussion with study participants and trained HIV healthcare providers from two quantitative studies evaluating the app‐based self‐test strategy. Our paper reveals how fear, apathy, judgement, frustration and comfort arise in testing encounters using the app and in previous testing experiences, as well as how this relates to care providers and test materials. Attending to affective aspects of this app‐based self‐testing practice makes visible certain affordances and limitations of the app within the therapeutic encounter and illustrates how mHealth can contribute to HIV care.

2 March 2016 in Canadian Journal on Aging / La Revue canadienne du vieillissement
Verified
Journal Article
Closed access
PDF file
IWIsabelle Wallach
Isabelle Wallach
XDXuân Ducandas
Xuân Ducandas
MMMichel Martel
Michel Martel
RTRéjean Thomas
Réjean Thomas
This research examines obstacles faced by older people living with HIV in maintaining their significant social ties (family, friends) in the light of a double theoretical framework, inter-sectionality and the course of life. Favoring a qualitative methodology, this research is based on in-depth, semi-directed interviews with a diverse sample of 38 people living with HIV, aged 50-73 years. Analysis reveals that a significant proportion of participants have experienced ruptures or deterioration of close ties with intimates at the level of family or friends. The principal factors behind these difficulties are the past and present stigma associated with HIV and /or other social positions, long-term effects of HIV, issues related to aging and crosscutting effects of HIV and aging.